본문 바로가기

Pipeline

  • Home
  • R&D
  • Pipeline

Pipeline

img_rnd_pipeline1
img_rnd_pipeline2
  • ID11917

    Cachexia

  • ID11918

    CRPC

  • ID61901

    Solid tumor

  • ID11909

    IO

  • ID11911

    Hot tumor

  • ID11912

    Excl. tumor

  • ID11913

    Cold tumor

  • IDX1197

    Solid tumor
    PARP-i

  • * Licensed out to
      Idience in Aug 2019

  • ID11026

    NASH

  • ID11906

    NASH-F4

  • ID11910

    NASH-F4

  • ID11905

    NASH
    ATX

  • ID11915

    AD

  • ID11046

    Pain

  • ID11908

    AD

  • ID11914

    AD

IO: ImmunoOncology, CRPC: Castration-Resistant Prostate Cancer, NASH: Non-Alcoholic SteatoHepatitis, AD: Alzheimer’s Disease
A2A: ATX: Autotaxin, FXR: Farnesoid X Receptor, CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, NO/PDE: Nitric Oxide/Phosphodiesterase E
VEGF-A/NRP1: Vascular Endothelial Growth Factor-A/Neuropilin-1, GLP-1R: Glucagon-Like Peptide-1 Receptor, GPR40: G-Protein-coupled Receptor 40

ico_exit

Oncology

ID11902

- A2A receptor selective antagonist for the treatment of solid tumors
- Nanomolar binding affinity, improved PK profiles and simple CMC
- Partial responses shown in murine colon cancer syngeneic model
- Potential to be developed as a combination agent with Immuno-Oncology drug and others

ico_exit

Oncology

IDB0076

- Engineered anti-VEGF-A antibody (bevacizumab) with tumor-tissue penetration property for the
  treatment of solid tumors
- Improved drug distribution, sensitivity and anti-angiogenesis with immune-oncology potential
- Reduced toxicity by mitigating the binding affinity for NRP1

ico_exit

Liver Disease(NASH)

ID11903

- Potent non-steroid Farnesoid X Receptor (FXR) agonist for the treatment of
  Non-Alcoholic SteatoHepatitis (NASH)
- Potent in vitro activities, selective and safe
- Showed high potency in STAM NASH model

ico_exit

CNS

ID11904

- Adenosine A2A and A1 receptor dual antagonist to improve both motor and non-motor
  symptoms in Parkinson’s disease
- A non-dopaminergic approach to avoid dopamine agonists’ side effects and the worsening of
  symptoms before next dose

ico_exit

Ophthalmology

ID11901

- Nitric oxide-donating PDE 5/6 dual inhibitor for the treatment of glaucoma and dry AMD
- First-in-class targeted; Potent and safe ocular treatment with novel MoAs
- Outstanding in vitro activities, more potent than sildenafil and avanafil

ico_exit

Ophthalmology

ID13010

- Engineered anti-VEGF-A antibody fragment (ranibizumab) with tissue penetration property for
  the treatment of wet Age-related Muscular Degeneration (AMD)
- Improved retinal distribution and permeability compared to commercial anti-VEGF drugs
- Potential to be developed as an eye drop because of the improved permeability

ico_exit

Metabolic Disease

ID11052

- Oral ‘small molecule’ GLP-1 receptor agonist for the treatment of type 2 diabetes
- Potent agonistic activity on human GLP-1 receptor and high safety margin over
  hERG inhibition
- Higher cost benefit when compared with oral peptide therapeutics

ico_exit

Metabolic Disease

ID11014

- First-in-class oral GPR40 agonist for the treatment of type 2 diabetes
- Potent anti-diabetic activity while not causing weight gain
- Low risk of hypoglycemia and Drug-Induced Liver Injury (DILI)

TOP